Geron is a commercial-stage biopharmaceutical company focused on developing therapies for blood cancers through telomerase inhibition. Its work centers on hematologic malignancies, including myelodysplastic syndromes, myelofibrosis, and acute myeloid leukemia.
The company's lead product, Imetelstat, is a first-in-class telomerase inhibitor that has been commercialized in the United States for the treatment of relapsed or refractory myelodysplastic syndromes. This marks a significant milestone as one of the few therapies of its kind available to patients in this indication.
Geron operates primarily in the United States. The company describes its approach as patient-centric, emphasizing a culture of moving quickly but thoughtfully in its drug development and commercialization efforts.
